HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N1- (4- (3- isopropyl- 2- methylindazol- 5- yl)pyrimidin- 2- yl)- N4- tetrahydropyran- 4- yl- cyclohexane- 1,4- diamine

a CDK9 inhibitor with antineoplastic activity; structure in first source

Also Known As:

LY2857785

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Aggarwal, Amit: 1 article (06/2014)
2.	Ajamie, Rose T: 1 article (06/2014)
3.	Carballares, Santiago: 1 article (06/2014)
4.	Cronier, Damien M: 1 article (06/2014)
5.	Donoho, Gregory P: 1 article (06/2014)
6.	Du, Jian: 1 article (06/2014)
7.	Fales, Kevin R: 1 article (06/2014)
8.	Foreman, Robert T: 1 article (06/2014)
9.	Gaynor, Richard B: 1 article (06/2014)
10.	Halstead, Bart W: 1 article (06/2014)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2023 - "These results suggest that LY2857785 induces cell death of ATL cells by MCL-1-dependent apoptosis and autophagy and has anti-tumor activity." 01/01/2023 - "Finally, LY2857785 significantly decreased the growth of ATL tumor xenografts. " 01/01/2023 - "Here, we investigated the effect of LY2857785, a novel CDK9 selective inhibitor, on cell death in ATL-related cell lines in vitro, freshly isolated cells from ATL patients ex vivo, and on ATL tumor xenografts in NOD/SCID mice in vivo. "
2.	Leukemia 06/01/2014 - "Herein, we describe a potent CDK9 inhibitor, LY2857785, that significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)